News articles about Penumbra (NYSE:PEN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Penumbra earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.5580162058169 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

A number of research firms recently issued reports on PEN. BMO Capital Markets reaffirmed a “buy” rating and set a $96.00 price target on shares of Penumbra in a research note on Friday, October 13th. Canaccord Genuity upped their price target on shares of Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Zacks Investment Research downgraded shares of Penumbra from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Penumbra has an average rating of “Hold” and an average price target of $111.50.

Penumbra (PEN) traded down $0.95 during trading on Monday, reaching $95.30. 279,847 shares of the company were exchanged, compared to its average volume of 327,258. Penumbra has a 52 week low of $67.95 and a 52 week high of $116.35. The stock has a market capitalization of $3,230.00 and a P/E ratio of 453.81.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $79.17 million. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. The business’s revenue for the quarter was up 24.9% on a year-over-year basis. analysts anticipate that Penumbra will post -0.15 EPS for the current fiscal year.

In other news, Director Thomas Wilder sold 345 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $91.15, for a total value of $31,446.75. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Arani Bose sold 16,452 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $105.89, for a total transaction of $1,742,102.28. Following the completion of the sale, the insider now directly owns 728,680 shares in the company, valued at approximately $77,159,925.20. The disclosure for this sale can be found here. In the last three months, insiders sold 347,026 shares of company stock worth $35,271,762. Insiders own 13.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Penumbra (PEN) Receiving Somewhat Positive Press Coverage, Report Finds” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with's FREE daily email newsletter.